Dr. Joshua Hare To Present Longeveron Regenerative Stem Cell Research At The Sixth Annual Aspen BrainLab
NEWS PROVIDED BY
MIAMI, July 13, 2018 /PRNewswire/ — Longeveron LLC, a biopharmaceutical company that develops stem cell therapies for aging-related diseases, announced that Dr. Joshua Hare, Chief Science Officer, will present at the sixth annual Aspen BrainLab on July 14. Aspen BrainLab brings together leading scientists and medical experts in neurology and is organized by the Aspen Brain Institute, which supports international brain research to fight brain disease.
In his presentation, “Can Stem Cells Spark the Regenerative Powers of the Human Brain?,” Dr. Hare will discuss the role Longeveron manufactured mesenchymal stem cells play to treat a host of human diseases related to brain health, cognition, and mood including Alzheimer’s disease and Aging Frailty.
“As the population ages and all of our lifespans increase, it has become critical to develop treatments that address aging to improve quality of life. A key concern shared by many is the loss of cognitive function with aging. Research and clinical trials strongly support a role for cell based therapy in enhancing brain health throughout life, and there are important groundbreaking clinical trials ongoing now,” Dr. Hare said.
Dr. Hare’s presentation, part of the first session of the conference from 9 a.m. to 12:30 p.m. MDT, will be streamed live on Facebook https://tinyurl.com/aspenbrainlab and YouTube https://tinyurl.com/ablyoutubelivestream.
Longeveron (www.longeveron.com) is a regenerative medicine therapy company founded in 2014. Longeveron’s goal is to provide the first of its kind biological solution for aging-related diseases, and is dedicated to developing safe cell-based therapeutics to revolutionize the aging process and improve quality of life. The company’s research focus areas include Alzheimer’s disease, Aging Frailty, and the Metabolic Syndrome, and gratefully acknowledges the generous support of the National Institutes of Health, Alzheimer’s Association and Maryland Stem Cell Research Fund. Longeveron is also conducting a Phase 1 trial with the University of Maryland and Johns Hopkins University to study Hypoplastic Left Heart Syndrome, a rare indication that affects infants, supported through a grant from the Maryland Stem Cell Research Fund.
SOURCE Longeveron LLC